JCR Pharmaceuticals CoJCRRF 65 EBITDA Margin % is -11.98% as of Dec. 2025. GuruFocus rates JCRRF with a GF Score™ of 65/100 and a GF Value™ of $5.39 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, JCR Pharmaceuticals Co ranks worse than 59.16% on this metric.
JCR Pharmaceuticals Co (OTCPK:JCRRF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
JCR Pharmaceuticals Co EBITDA Margin % Related Terms
JCR Pharmaceuticals Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for JCR Pharmaceuticals Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JCRRF vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JCR Pharmaceuticals Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where JCR Pharmaceuticals Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JCR Pharmaceuticals Co (JCRRF) has a EBITDA Margin % of -11.98% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JCR Pharmaceuticals Co and its competitors. According to the industry distribution chart, JCR Pharmaceuticals Co ranks #565 out of 955 companies in the Drug Manufacturers industry, placing it in the top 59.2%.
Is JCR Pharmaceuticals Co's EBITDA Margin % too high?
JCR Pharmaceuticals Co's current EBITDA Margin % is -11.98%. Based on the distribution chart, JCR Pharmaceuticals Co ranks #565 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JCR Pharmaceuticals Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, JCR Pharmaceuticals Co ranks #565 out of 955 companies for EBITDA Margin %. This places JCR Pharmaceuticals Co in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JCR Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JCR Pharmaceuticals Co's current EBITDA Margin % is -11.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (JCRRF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.39, compared to a current price of $3.15 — trading 41.7% below its estimated fair value. The current EBITDA Margin % is -11.98%. JCR Pharmaceuticals Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For JCR Pharmaceuticals Co (JCRRF), the current EBITDA Margin % is -11.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JCR Pharmaceuticals Co (JCRRF) Overvalued in 2026?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued.
The current stock price of $3.15 is trading 41.7% below its estimated GF Value™ of $5.39.
GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for JCRRF:
EBITDA Margin %: -11.98%
GF Value™: $5.39 vs. price of $3.15 (41.7% below fair value)
No single metric tells the full story. See the JCRRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
65GF Score
Get the complete analysis for JCRRF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JCRRF has been successfully added to your 
